Intercept down 7% premarket

Despite the announcement of positive phase III results for obeticholic acid, shares of Intercept Pharmaceuticals (ICPT) are poised for a gap down at the open.

According to Adam Feuerstein, the product caused cardiovascular side effects in a separate phase II trial. This was disclosed in the company's recent 10-K. Intercept says the side effects are insignificant.

From other sites
Comments (1)
    , contributor
    Comments (37) | Send Message
    It will up 5% soon. shorts will be burnt.Medical studies use p-value of 5% for "statistical significance". This means 95% probability adverse effects were due to pure chance. This is great buying opportunity
    17 Mar 2014, 08:25 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs